胆囊结石形成机制及诊疗现状研究
|
摘要
胆囊结石是常见、多发的疾病,严重影响人们的健康和生活。其成因繁杂,涉及多种因素、多个环节,一直是临床研究的热点和难点。近年来国内外学者分别从代谢组学、蛋白组学、基因组学等多角度、多方面对胆囊结石成因及其形成机制进行探讨,因此,总结目前胆囊结石的形成机制方面的研究,提出相关防治措施具有重要的临床价值。该文从胆囊结石形成的诱发因素、临床手术治疗研究进展进行汇总分析,以期为探究胆囊结石的形成机制及临床防治提供一定思路与借鉴。
引文
[1]Bourgouin S,Lamblin G,Rose P,et al.Response to Re:Minimally invasive management of gallstone ileus with cholecystoduodenal fistula[J].ANZ J Surg,2019,89(3):267-268.
[2]孙逊,张静喆,章学林,等.LXRs/FXR介导的胆固醇/胆汁酸代谢链在疏肝利胆中药“从肝论治”胆固醇结石中的重要作用[J].中华中医药杂志,2017,32(3):1178-1180.
[3]李孔才,温海斌,李德,等.熊去氧胆酸联合胆宁片对胆石症患者胆汁成分和成石趋势的影响[J].吉林医学,2017,38(11):2060-2062.
[4]蒋兆彦,胡海,韩天权,等.胆固醇的肠肝循环:肝脏和小肠在胆石形成中的作用[J].外科理论与实践,2017,22(3):191-194.
[5]Tada H,Nomura A,Yamagishi M,et al.First case of sitosterolemia caused by double heterozygous mutations in ABCG5and ABCG8genes[J].J Clin Lipidol,2018,12(5):1164-1168.
[6]皮宇,高侃,朱伟云.机体胆汁酸肠-肝轴的研究进展[J].生理科学进展,2017,48(3):161-166.
[7]闫凛,梁超.胆固醇72-羟化酶的研究进展[J].临床医学进展,2018,8(1),64-68.
[8]任明,郭嵩,杨士勇,等.胆结石小鼠肝脏核受体基因LRH-1及其调控基因CYP7A1的表达[J].中国现代普通外科进展,2014,17(10):763-767.
[9]杨士勇,韩天权,时开网,等.胆结石病人肝脏核受体LRH-1及其调控基因表达的研究[J].中华肝胆外科杂志,2009,15(5):325-328.
[10]Jiang Z Y,Parini P,Eggertsen G,et al.Increased expression of LXR alpha,ABCG5,ABCG8,and SR-BI in the liver from normolipidemic,nonobese Chinese gallstone patients[J].Journal of Lipid Research,2008,49(2):464-472.
[11]Moschetta A,Bookout AL,Mangelsdorf DJ.Prevention of cholesterol gallstone disease by FXR agonists in a mouse model[J].Nature Medicine,2004,10(12):1352-1358.
[12]陈永生,吴硕东.胆囊功能与胆囊胆固醇结石[J].中国现代普通外科进展,2017,20(2):120-123.
[13]Lavoie B,Nausch B,Zane EA,et al.Disruption of gallbladder smooth muscle function is an early feature in the development of cholesterol gallstone disease[J].Neurogastroenterology &Motility,2012,24(7):e313-e324.
[14]周冰冰,王学梅,张茜,等.代谢综合征与胆囊结石的相关性分析[J].临床肝胆病杂志,2017,33(5):880-882.
[15]张静,刘静,陈丹,等.新疆地区体检人群胆囊结石与代谢综合征及其组分相关性分析[J].中华实用诊断与治疗杂志,2016,30(9):894-896.
[16]Chen Y,Kong J,Wu S.Cholesterol gallstone disease:focusing on the role of gallbladder[J].Laboratory investigation;ajournal of technical methods and pathology,2015,95(2):124.
[17]Levinson SS.High-Density Lipoprotein Metabolism and Reverse Cholesterol Transport[J].Journal of Clinical Ligand Assay,2006,29(1):23-28.
[18]Ruhl CE,Everhart JE.Association of diabetes,serum insulin,and C-peptide with gallbladder disease[J].Hepatology,2000,31(2):299-303.
[19]陈海平,杨文军,邱招涨,等.雌性激素及脂质代谢异常在胆囊结石发病中的作用[J].肝胆胰外科杂志,2009,21(4):282-284.
[20]陈孝平,汪建平.外科学[M].9版.北京:人民卫生出版社,2018:461-462.
[21]黄志强.胆囊结石[M]//吴阶平,裘法祖,吴孟超,等.黄家驷外科学(中).7版.北京:人民卫生出版社,2008:1799.
[22]卢绮萍.关注胆囊结石病治疗策略的争议、共识与发展[J].腹部外科,2017,30(5):334-337.
[23]郭绍红译,Maria Coats,Sami M Shimi.胆囊切除术与消化道癌症的风险:一项系统性综述[J].中国微创外科杂志,2017(1):27-32.
[24]赵海鹰,刘金钢.从过度和不足角度看无症状性胆囊结石与胆囊息肉的规范化治疗[J].中国实用外科杂志,2016,36(10):1053-1057.
[25]宋睿,杜国平.保胆取石的研究现状及结石复发的探究[J].医学综述,2017,23(21):144-148.
[26]郑学彪.微创保胆取石术与腹腔镜胆囊切除术治疗胆结石的手术效果分析[J].中外医学研究,2019,17(4):147-148.
[27]Hyun JJ,Lee HS,Kim CD,et al.Efficacy of Magnesium trihydrate of Ursodeoxycholic Acid and Chenodeoxycholic Acid for Gallstone Dissolution:A Prospective Multicenter Trial[J].Gut &Liver,2015,9(4):547-555.
[28]陈跃,冯连吉,李全朋,等.中西药联合应用溶解胆囊结石的实验研究[J].南京医科大学学报(自然科学版),2016,36(10):1188-1191,1197.
[29]Meng ZW,Han SH,Zhu JH,et al.Risk Factors for Cholangiocarcinoma After Initial Hepatectomy for Intrahepatic Stones[J].World J Surg,2017,41(3):835-843.
[30]唐乾利,刘祖军,伍松合,等.大黄灵仙胶囊降低胆石症术后残石率及复发率疗效观察[J].新中医,2002,34(6):17-19.
[31]俞渊,王兵,唐乾利,等.大黄灵仙颗粒调控IL-6、EGR-1表达治疗胆石症的实验研究[J].辽宁中医杂志,2017,44(7):1514-1517.
[32]唐乾利,王兵,俞渊,等.大黄灵仙颗粒对慢性肝纤维化胆石病兔干预作用[J].武汉大学学报(医学版),2017,38(1):6-10.
[33]唐乾利,黄欣,俞渊,等.兔胆石症的代谢组学特征及大黄灵仙胶囊的干预作用[J].医学导报,2013,32(12):1538-1542.
[34]唐乾利,吕震,王兵,等.大黄灵仙胶囊调控ABCB11和ABCC2干预胆结石形成的作用机制研究[J].重庆医学,2018,47(1):4-10.
[2]孙逊,张静喆,章学林,等.LXRs/FXR介导的胆固醇/胆汁酸代谢链在疏肝利胆中药“从肝论治”胆固醇结石中的重要作用[J].中华中医药杂志,2017,32(3):1178-1180.
[3]李孔才,温海斌,李德,等.熊去氧胆酸联合胆宁片对胆石症患者胆汁成分和成石趋势的影响[J].吉林医学,2017,38(11):2060-2062.
[4]蒋兆彦,胡海,韩天权,等.胆固醇的肠肝循环:肝脏和小肠在胆石形成中的作用[J].外科理论与实践,2017,22(3):191-194.
[5]Tada H,Nomura A,Yamagishi M,et al.First case of sitosterolemia caused by double heterozygous mutations in ABCG5and ABCG8genes[J].J Clin Lipidol,2018,12(5):1164-1168.
[6]皮宇,高侃,朱伟云.机体胆汁酸肠-肝轴的研究进展[J].生理科学进展,2017,48(3):161-166.
[7]闫凛,梁超.胆固醇72-羟化酶的研究进展[J].临床医学进展,2018,8(1),64-68.
[8]任明,郭嵩,杨士勇,等.胆结石小鼠肝脏核受体基因LRH-1及其调控基因CYP7A1的表达[J].中国现代普通外科进展,2014,17(10):763-767.
[9]杨士勇,韩天权,时开网,等.胆结石病人肝脏核受体LRH-1及其调控基因表达的研究[J].中华肝胆外科杂志,2009,15(5):325-328.
[10]Jiang Z Y,Parini P,Eggertsen G,et al.Increased expression of LXR alpha,ABCG5,ABCG8,and SR-BI in the liver from normolipidemic,nonobese Chinese gallstone patients[J].Journal of Lipid Research,2008,49(2):464-472.
[11]Moschetta A,Bookout AL,Mangelsdorf DJ.Prevention of cholesterol gallstone disease by FXR agonists in a mouse model[J].Nature Medicine,2004,10(12):1352-1358.
[12]陈永生,吴硕东.胆囊功能与胆囊胆固醇结石[J].中国现代普通外科进展,2017,20(2):120-123.
[13]Lavoie B,Nausch B,Zane EA,et al.Disruption of gallbladder smooth muscle function is an early feature in the development of cholesterol gallstone disease[J].Neurogastroenterology &Motility,2012,24(7):e313-e324.
[14]周冰冰,王学梅,张茜,等.代谢综合征与胆囊结石的相关性分析[J].临床肝胆病杂志,2017,33(5):880-882.
[15]张静,刘静,陈丹,等.新疆地区体检人群胆囊结石与代谢综合征及其组分相关性分析[J].中华实用诊断与治疗杂志,2016,30(9):894-896.
[16]Chen Y,Kong J,Wu S.Cholesterol gallstone disease:focusing on the role of gallbladder[J].Laboratory investigation;ajournal of technical methods and pathology,2015,95(2):124.
[17]Levinson SS.High-Density Lipoprotein Metabolism and Reverse Cholesterol Transport[J].Journal of Clinical Ligand Assay,2006,29(1):23-28.
[18]Ruhl CE,Everhart JE.Association of diabetes,serum insulin,and C-peptide with gallbladder disease[J].Hepatology,2000,31(2):299-303.
[19]陈海平,杨文军,邱招涨,等.雌性激素及脂质代谢异常在胆囊结石发病中的作用[J].肝胆胰外科杂志,2009,21(4):282-284.
[20]陈孝平,汪建平.外科学[M].9版.北京:人民卫生出版社,2018:461-462.
[21]黄志强.胆囊结石[M]//吴阶平,裘法祖,吴孟超,等.黄家驷外科学(中).7版.北京:人民卫生出版社,2008:1799.
[22]卢绮萍.关注胆囊结石病治疗策略的争议、共识与发展[J].腹部外科,2017,30(5):334-337.
[23]郭绍红译,Maria Coats,Sami M Shimi.胆囊切除术与消化道癌症的风险:一项系统性综述[J].中国微创外科杂志,2017(1):27-32.
[24]赵海鹰,刘金钢.从过度和不足角度看无症状性胆囊结石与胆囊息肉的规范化治疗[J].中国实用外科杂志,2016,36(10):1053-1057.
[25]宋睿,杜国平.保胆取石的研究现状及结石复发的探究[J].医学综述,2017,23(21):144-148.
[26]郑学彪.微创保胆取石术与腹腔镜胆囊切除术治疗胆结石的手术效果分析[J].中外医学研究,2019,17(4):147-148.
[27]Hyun JJ,Lee HS,Kim CD,et al.Efficacy of Magnesium trihydrate of Ursodeoxycholic Acid and Chenodeoxycholic Acid for Gallstone Dissolution:A Prospective Multicenter Trial[J].Gut &Liver,2015,9(4):547-555.
[28]陈跃,冯连吉,李全朋,等.中西药联合应用溶解胆囊结石的实验研究[J].南京医科大学学报(自然科学版),2016,36(10):1188-1191,1197.
[29]Meng ZW,Han SH,Zhu JH,et al.Risk Factors for Cholangiocarcinoma After Initial Hepatectomy for Intrahepatic Stones[J].World J Surg,2017,41(3):835-843.
[30]唐乾利,刘祖军,伍松合,等.大黄灵仙胶囊降低胆石症术后残石率及复发率疗效观察[J].新中医,2002,34(6):17-19.
[31]俞渊,王兵,唐乾利,等.大黄灵仙颗粒调控IL-6、EGR-1表达治疗胆石症的实验研究[J].辽宁中医杂志,2017,44(7):1514-1517.
[32]唐乾利,王兵,俞渊,等.大黄灵仙颗粒对慢性肝纤维化胆石病兔干预作用[J].武汉大学学报(医学版),2017,38(1):6-10.
[33]唐乾利,黄欣,俞渊,等.兔胆石症的代谢组学特征及大黄灵仙胶囊的干预作用[J].医学导报,2013,32(12):1538-1542.
[34]唐乾利,吕震,王兵,等.大黄灵仙胶囊调控ABCB11和ABCC2干预胆结石形成的作用机制研究[J].重庆医学,2018,47(1):4-10.